Sarajevo, Bosnia and Herzegovina, 08 March, 2021 - Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), a subsidiary of MicroPort Scientific Corporation (00853.HK), recently received registration approval from the Agency for Medicines and Medical Devices of Bosnia and Herzegovina (ALMBiH) for three of its proprietary products, namely Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), Foxtrot® Pro PTCA Coronary Balloon Catheter (Foxtrot® Pro), and Foxtrot® NC PTCA Balloon Catheter (Foxtrot® NC).
Firehawk® is a drug-eluting stent (DES) with patented grooved struts and a precision targeting drug-releasing technology. Firehawk®’s hair-thin, dense CoCr alloy struts consist of nearly 600 meticulously cut grooves through which the drug is delivered, using fully automated 3D printing and groove-filling techniques. Firehawk® combines the merits of bare metal and drug-eluting stents, ensuring the same clinical efficacy but with a significantly lower drug loading.
The Foxtrot® Pro Balloon Catheter is a rapid exchange balloon catheter designed to enlarge a patient’s lesion prior to stent implantation in PTCA procedures. With excellent crossability and traceability, it offers additional solutions for more complex lesions. Its innovative, ultra-long hydrophilic coating significantly improves its crossability and pushability, making it suitable for use in balloon-stent kissing techniques.
Of equal, superb quality is the Foxtrot® NC Balloon Catheter, used for both pre-dilation of endovascular lesions prior to stent implantation and for precise post-dilation of stents after their implantation.
The approval in Bosnia and Herzegovina of these three outstanding products offered by MicroPort® fully demonstrates the company’s excellent product portfolio in the field of coronary intervention, further expanding the company’s global presence. The future of MicroPort® will see the delivery of high quality and accessible medical devices to Bosnia and Herzegovina, providing integrated medical solutions for local patients and doctors in the field of coronary intervention.